Inhibrx Biosciences (INBX) Change in Account Payables (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Change in Account Payables came in at -$829000.0 in Q4 2025, up 73.42% year-on-year from -$478027.5 in Q4 2024, and up 45.42% on a QoQ basis from -$1.5 million in Q3 2025.
Inhibrx Biosciences (INBX) Change in Account Payables (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Change in Account Payables data on file, last reported at -$829000.0 in Q4 2025.
- On a quarterly basis, Change in Account Payables rose 73.42% year-over-year to -$829000.0 in Q4 2025; TTM through Dec 2025 was -$3.3 million, a 118.44% decrease from a year earlier, with the FY2025 full-year figure at -$3.3 million, down 118.44% from the prior year.
- Change in Account Payables for Q4 2025 stood at -$829000.0, up from -$1.5 million in the prior quarter.
- Over the last five years, Change in Account Payables for INBX reached as high as $17.4 million in Q2 2024 and fell as low as -$3.1 million in Q4 2024.
- Historically, Change in Account Payables has averaged $1.6 million across 3 years, with a median of -$525000.0 in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 73.42% in 2025 and fell as far as 237.56% in 2025.
- Year by year, Change in Account Payables stood at $2.9 million in 2023, then plunged by 207.18% to -$3.1 million in 2024, then soared by 73.42% to -$829000.0 in 2025.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$829000.0 in Q4 2025, -$1.5 million in Q3 2025, and -$600000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -829,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -829,000.00 |
| Dec 31, 2025 | -829,000.00 |
| Sep 30, 2025 | -1.52 Mn |
| Sep 30, 2025 | -1.52 Mn |
| Jun 30, 2025 | -600,000.00 |
| Jun 30, 2025 | -600,000.00 |
| Mar 31, 2025 | -353,000.00 |
| Mar 31, 2025 | -353,000.00 |
| Dec 31, 2024 | -3.12 Mn |
| Dec 31, 2024 | -3.12 Mn |
| Sep 30, 2024 | -450,000.00 |
| Sep 30, 2024 | -450,000.00 |
| Jun 30, 2024 | 17.42 Mn |
| Jun 30, 2024 | 17.42 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Sep 30, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.59 Mn |